<DOC>
	<DOCNO>NCT02141347</DOCNO>
	<brief_summary>A Phase I , Open-Label , Multicentre Study Assess Safety , Tolerability , PK Preliminary Anti-tumor Activity give monotherapy Tremelimumab Tremelimumab combination MEDI4736 Japanese Patients Advanced Solid Malignancies , give monotherapy tremelimumab Second- Third-line Treatment Japanese Subjects Unresectable Pleural Peritoneal Malignant Mesothelioma</brief_summary>
	<brief_title>Ph1 Assess Safety , Tolerability Tremelimumab/ Tremelimumab+MEDI4736 Japanese Solid Malignancies/ Mesothelioma</brief_title>
	<detailed_description>Primary objective Part A : To investigate safety tolerability tremelimumab give Japanese patient advance solid malignancy define dose ( ) clinical evaluation . Part B : To investigate safety tolerability tremelimumab combination MEDI4736 give Japanese patient advance solid malignancy define dose ( ) clinical evaluation . Part C : To investigate safety tolerability tremelimumab give Japanese patient unresectable pleural peritoneal malignant mesothelioma .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Part A B : 1 . Japanese age least 20 year old time enrollment . 2 . Histological cytological confirmation solid malignant tumor exclude lymphoma refractory standard therapy standard therapy exist . 3 . ECOG Performance Status 01 deterioration previous 2 week minimum life expectancy 12 week time randomization . 4 . At least one lesion ( measurable and/or nonmeasurable ) accurately assessed baseline CT , MRI plain Xray suitable repeat assessment . 5 . Adequate bone marrow , hepatic , renal function 6 . Willingness provide consent archival biopsy sample available . 1 . Received prior treatment monoclonal antibody Programmed death 1 ( PD1 ) , Programmed death ligand 1 ( PDL1 ) CTLA4 ( eg , ipilimumab ) 2 . The last dose prior chemotherapy radiation therapy receive less 2 week prior randomization 3 Currently receive systemic corticosteroid immunosuppressive medication medical condition require chronic use corticosteroid . 4 . Receipt live attenuate vaccination within 30 day start tremelimumab treatment 5 . Active , untreated central nervous system ( CNS ) metastasis ( subject brain metastasis identify screen 6 . History malignancy unless subject diseasefree least 3 year . 7 . Any unresolved chronic toxicity CTCAE grade â‰¥2 previous anticancer therapy time randomization , 8 . Major surgical procedure within 30 day start Part C : 1 . Japanese age 20 time consent 2 . Histologically and/or cytologically confirm pleural peritoneal malignant mesothelioma 3 . Disease amenable curative surgery 4 . ECOG Performance status 01 5 . Progressed previous receipt 12 prior systemic treatment advance disease include firstline pemetrexed ( antifolate ) base regimen combination platinum agent . 6 . Measurable disease , define least 1 lesion ( measurable ) accurately assessed baseline compute tomography CT MRI suitable repeat assessment . 7 . Adequate bone marrow , hepatic , renal function 1 . Subjects fail 2 prior systemic treatment regimen advance malignant mesothelioma 2 . Received prior mAb CTLA4 , PD1 PDL1 3 . History chronic inflammatory autoimmune disease . 4 . Symptomatic , untreated CNS metastasis . 5 . Any serious uncontrolled medical disorder active infection would impair subject 's ability receive investigational product . 6 . History malignancy . 7 . History diverticulitis , inflammatory bowel disease , sarcoidosis syndrome 8 . Currently receive systemic corticosteroid immunosuppressive medication . 9 . Vaccinated live attenuate vaccine within 30 day prior start tremelimumab treatment 10 . Not recovered toxicity associate prior cancer treatment acceptable baseline status , NCI CTCAE ver.3.0 Grade 0 1</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>